System of Matrix Metalloproteinases and Cytokine Secretion in Type 2 Diabetes Mellitus and Impaired Carbohydrate Tolerance Associated with Arterial Hypertension

Кологривова, И. В.; Суслова, Т. Е.; Koshelskaya, O. A.; Vinnitskaya, I. V.; Трубачева, О. А.

doi:10.1007/s10517-014-2413-4

Cited by 20 publications

(9 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, healthy subjects were not enrolled and circulating Th17 levels were not measured in this study [7]. Consistent with these results, many clinical studies have found that circulating IL-17 levels significantly increased in hypertensive patients [13, 14]. Moreover, Yao et al found that serum IL-17 levels were significantly higher in subjects with prehypertension, defined as systolic BP of 120 to 139 mm Hg or diastolic BP of 80 to 89 mm Hg, than in subjects with optimal BP, defined as systolic BP < 120 mm Hg and diastolic BP < 80 mm Hg [31].…”

Section: Discussionsupporting

confidence: 60%

Circulating Th1, Th2, and Th17 Levels in Hypertensive Patients

Cheng

et al. 2017

Disease Markers

View full text Add to dashboard Cite

Background Evidence from experimental studies showed that Th1, Th2, and Th17 play a pivotal role in hypertension and target organ damage. However, whether changes in the circulating Th1, Th2, and Th17 levels are associated with nondipper hypertension and carotid atherosclerotic plaque in hypertension has yet to be investigated. Methods Th1, Th2, and Th17 levels were detected using a flow cytometric analysis, and their related cytokines were measured by enzyme-linked immunosorbent assay in 45 hypertensive patients and 15 normotensive subjects. Results The frequencies of Th1 and Th17 in hypertensive patients, especially in nondipper patients and patients with carotid atherosclerotic plaque, were markedly higher than those in the control group; this was accompanied by higher IFN-γ and IL-17 levels. In contrast, the Th2 frequencies and IL-4 levels in hypertensive patients, especially in nondipper patients and patients with carotid atherosclerotic plaque, were significantly lower than those in the control group. Conclusions The changes in Th1, Th2, and Th17 activity are associated with the onset of the nondipper type and carotid atherosclerotic plaque in hypertensive patients.

show abstract

Section: Discussionsupporting

confidence: 60%

Circulating Th1, Th2, and Th17 Levels in Hypertensive Patients

Cheng

et al. 2017

Disease Markers

View full text Add to dashboard Cite

show abstract

“…The study reported inflammatory cytokines disorder was used as critical early biomarkers for estimating the T2DM risks and complications 47,48. T2DM patients had significantly higher levels of inflammatory markers interleukin-1B (IL-1B) and IL-6, while IL-10 showed lower levels, compared with non-diabetic patients 47,49. STAT1 is highly expressed in patients with T2DM.…”

Section: Resultsmentioning

confidence: 99%

<p>A Network Pharmacology-Based Strategy For Predicting Active Ingredients And Potential Targets Of LiuWei DiHuang Pill In Treating Type 2 Diabetes Mellitus</p>

He¹,

Huang²,

Zhang³

et al. 2019

DDDT

View full text Add to dashboard Cite

BackgroundTraditional Chinese medicine (TCM) formulations have proven to be advantageous in clinical treatment and prevention of disease. LiuWei DiHuang Pill (LWDH Pill) is a TCM that was employed to treat type 2 diabetes mellitus (T2DM). However, a holistic network pharmacology approach to understanding the active ingredients and the therapeutic mechanisms underlying T2DM has not been pursued.MethodsA network pharmacology approach including drug-likeness evaluation, oral bioavailability prediction, virtual docking, and network analysis has been used to predict the active ingredients and potential targets of LWDH Pill in the treatment of type 2 diabetes.ResultsThe comprehensive network pharmacology approach was successfully to identify 45 active ingredients in LWDH Pill. 45 active ingredients hit by 163 potential targets related to T2DM. Ten of the more highly predictive components (such as :quercetin, Kaempferol, Stigmasterol, beta-sitosterol, Kadsurenone, Diosgenin, hancinone C, Hederagenin, Garcinone B, Isofucosterol) are involved in anti-inflammatory, anti-oxidative stress, and the reduction of beta cell damage. LWDH Pill may play a role in the treatment of T2DM and its complications (atherosclerosis and nephropathy) through the AGE-RAGE signaling pathway, TNF signaling pathway, and NF-kappa B signaling pathway.ConclusionBased on a systematic network pharmacology approach, our works successfully predict the active ingredients and potential targets of LWDH Pill for application to T2DM and helps to illustrate mechanism of action on a comprehensive level. This study provides identify key genes and pathway associated with the prognosis and pathogenesis of T2DM from new insights, which also demonstrates a feasible method for the research of chemical basis and pharmacology in LWDH Pill.

show abstract

“…It has been reported that inflammatory cytokines are elevated in patients with T2D. For example, IL-17, which was reported to suppress differentiation of preadipocytes and impair adipsin expression in adipocytes [25], was elevated in patients with T2D [26, 27]. Furthermore, IL-17 has been associated with insulin resistance in animal models [28].…”

Section: Discussionmentioning

confidence: 99%

Association Between Serum Adipsin Levels and Insulin Resistance in Subjects With Various Degrees of Glucose Intolerance

Wang

Lee

et al. 2018

Journal of the Endocrine Society

View full text Add to dashboard Cite

ContextThe association between adipsin and glucose metabolism in human subjects remains unclear.ObjectiveWe investigated the associations between adipsin and insulin resistance/β-cell function in subjects with various degrees of glucose intolerance.DesignFasting blood samples were collected for measurements of fasting plasma glucose (FPG), insulin, and adipsin. An oral glucose tolerance test was conducted in subjects with no history of diabetes.SettingThis study was conducted at a medical center.PatientsWe enrolled 240 subjects with no history of diabetes and 80 patients with known type 2 diabetes (T2D) on diet control or metformin monotherapy.Main Outcome Measure β-cell function and insulin resistance were assessed using the homeostasis model assessment (HOMA-β and HOMA-IR, respectively).ResultsLevels of serum adipsin were higher in subjects with normal glucose tolerance (4.0 ± 1.1 µg/mL) or prediabetes (4.0 ± 1.5 µg/mL) compared with subjects with newly diagnosed diabetes (3.8 ± 1.1 µg/mL) or with known T2D on diet control (3.4 ± 1.0 µg/mL) or metformin monotherapy (3.0 ± 1.0 µg/mL, P < 0.001). There was no significant association between adipsin and HOMA-β. In contrast, there was an independent negative association between adipsin and HOMA-IR (β coefficient −0.414, 95% CI −0.720 to −0.109, P = 0.008). The association was more prominent in subjects with a body mass index (BMI) ≥25 kg/m2 or an FPG ≥100 mg/dL (P interaction < 0.001 and 0.014, respectively).ConclusionsSerum adipsin levels were negatively associated with insulin resistance, especially in subjects with a BMI ≥25 kg/m2 or an FPG ≥100 mg/dL.

show abstract

System of Matrix Metalloproteinases and Cytokine Secretion in Type 2 Diabetes Mellitus and Impaired Carbohydrate Tolerance Associated with Arterial Hypertension

Cited by 20 publications

References 6 publications

Circulating Th1, Th2, and Th17 Levels in Hypertensive Patients

Circulating Th1, Th2, and Th17 Levels in Hypertensive Patients

<p>A Network Pharmacology-Based Strategy For Predicting Active Ingredients And Potential Targets Of LiuWei DiHuang Pill In Treating Type 2 Diabetes Mellitus</p>

Association Between Serum Adipsin Levels and Insulin Resistance in Subjects With Various Degrees of Glucose Intolerance

Contact Info

Product

Resources

About